Glasgow Biotech Mironid Secures $34 Million in Latest Series B Funding Round

Glasgow Biotech Mironid secured $34 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Glasgow Biotech Mironid Raises $34 million in Funding

Glasgow Biotech Mironid Secures £34m Series B Funding. The Company is led by an industry-experienced management team and supported by a strong advisory network and blue-chip investors including Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures.

Investors Behind the Funding

The round was backed by an industry-experienced management team. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Glasgow Biotech Mironid operates in Healthcare & Life Sciences. Glasgow Biotech Mironid's financing adds to recent private-market activity.

Strategic Use of Funds

Develop treatments for Autosomal Dominant Polycystic Kidney Disease.

Looking Ahead

Glasgow Biotech Mironid Secures £34m Series B Funding

Source reference: original announcement/article.